This page shows the publications co-authored by Judy Garber and Michele Hacker.
Tung N, Hacker MR, Garber JE. Reply to S. Takamizawa et al. J Clin Oncol. 2020 Aug 10; 38(23):2700-2701.
Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 May 10; 38(14):1539-1548.
Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, Garber JE. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Res Treat. 2014 Jul; 146(1):175-82.
Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020; 6:19.
Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer. 2016; 2:16002.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.